GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » EV-to-EBIT

Organon (Organon) EV-to-EBIT

: 10.53 (As of Today)
View and export this data going back to 2021. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Organon's Enterprise Value is $12,633 Mil. Organon's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,200 Mil. Therefore, Organon's EV-to-EBIT for today is 10.53.

The historical rank and industry rank for Organon's EV-to-EBIT or its related term are showing as below:

OGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.74   Med: 9.39   Max: 10.74
Current: 10.54

During the past 6 years, the highest EV-to-EBIT of Organon was 10.74. The lowest was 3.74. And the median was 9.39.

OGN's EV-to-EBIT is ranked better than
72.16% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs OGN: 10.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Organon's Enterprise Value for the quarter that ended in Dec. 2023 was $11,753 Mil. Organon's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,200 Mil. Organon's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 10.21%.


Organon EV-to-EBIT Historical Data

The historical data trend for Organon's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only - - 9.02 9.92 9.79

Organon Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.92 10.38 9.99 10.59 9.79

Competitive Comparison

For the Drug Manufacturers - General subindustry, Organon's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organon EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Organon's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Organon's EV-to-EBIT falls into.



Organon EV-to-EBIT Calculation

Organon's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=12632.699/1200
=10.53

Organon's current Enterprise Value is $12,633 Mil.
Organon's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,200 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organon  (NYSE:OGN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Organon's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=1200/11753.12692
=10.21 %

Organon's Enterprise Value for the quarter that ended in Dec. 2023 was $11,753 Mil.
Organon's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,200 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organon EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Organon's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Organon (Organon) Business Description

Traded in Other Exchanges
Address
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.
Executives
Kirke Weaver officer: Gen. Counsel & Corp. Secy. 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman officer: General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco officer: Corporate Controller 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler officer: Chief Commercial Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita officer: Head of Global Business Svcs 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr. officer: Head of Manufacturing 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione officer: Chief Human Resources Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah director 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter officer: Hd of Ext. Affairs and ESG 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan officer: Head of Research & Development 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139